Addex receives $3m to research substance use therapy

03 Aug 2023
www.pharmaceutical-technology.com
Phase 2Phase 3Phase 1License out/in
Addex receives $3m to research substance use therapy
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
Addex receives $3m to research substance use therapy
Preview
Source: Pharmaceutical Technology
Addex also raised $5m in funding for providing a cash runway to achieve development milestones for drug partnerships with Janssen and Indivior. Image Credit: Golden Sikorka / Shutterstock.
Addex Therapeutics and Indivior have extended their research agreement for the drug discovery of novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates for treating substance use disorders.
The new agreement will extend until 30 June 2024, and Addex will receive SFr2.7m ($3m) from Indivior for drug research and discovery. Furthermore, Addex will retain exclusive rights to an independent GABAB PAM programme for treating chronic cough.
The agreement started in 2018, with an initial upfront payment of $5m and milestone-based payments of up to $330m. The companies have extended the partnership multiple times with additional payments from Indivior.
Addex CEO Tim Dyer said: “We are excited to continue working closely with Indivior in this promising application of our allosteric modulator discovery platform.”
Addex also raised $5m in funding for providing a cash runway to achieve development milestones for drug partnerships with Janssen and Indivior, as per the 5 April 2023 press release.
Addex’s ADX71149, a PAM of metabotropic glutamate receptor 2 (mGlu2 PAM), developed in collaboration with Janssen Pharmaceuticals, is in a Phase IIa proof of concept clinical trial (NCT04836559) for the treatment of epilepsy.
Following a review of cohort I data by the Independent Interim Review Committee in May 2023, the companies plan to continue the study. The study’s cohort I has progressed to Part II and cohort II is currently recruiting patients.
Other investigative drugs for substance use disorder treatment include Phase I/II (NCT05322954) Revive Therapeutics’ oral psilocybin for the treatment of methamphetamine use disorder (MUD) and Phase III Almatica Pharma’s ALM-006.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.